Valuation: BenevolentAI S.A.

Market Cap 8.34M 11.09M 9.96M 9.19M 15.58M 1.05B 15.77M 110M 43.77M 552M 41.64M 40.75M 1.75B P/E 2024 *
-
P/E 2025 -
Enterprise Value -9.9M -13.17M -11.82M -10.92M -18.5M -1.25B -18.73M -131M -51.99M -656M -49.45M -48.4M -2.08B EV / Sales 2024
2.15x
EV / Sales 2025 -1.09x
Free-Float
59.54%
Yield 2024 *
-
Yield 2025 -
3 years 0.07
Extreme 0.07
2.66
5 years 0.07
Extreme 0.07
10
10 years 0.07
Extreme 0.07
10
Manager TitleAgeSince
Chief Operating Officer 50 01/02/2014
Director of Finance/CFO - 16/10/2024
Chief Tech/Sci/R&D Officer - 01/04/2024
Director TitleAgeSince
Director/Board Member 70 01/07/2020
Chairman 70 02/05/2024
Director/Board Member 58 01/11/2013
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/24 A Buy

Director

10,000 0.0070%
2/9/24 A Buy

Director

2,066 0.0014%
2/9/24 A Buy

Director

20,000 0.0140%
Change 5-day change 1-year change 3-year change Capi.($)
-14.74%-.--%-.--%-91.47% 11.59M
-3.10%-4.19%+32.67%+59.47% 63.48B
+0.33%+0.33%+10.16%+78.07% 54.55B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 44.75B
-1.30%-4.80%+16.05%+114.76% 41.62B
+1.26%-5.26%+221.12%+900.64% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+1.11%+15.18%+60.27%+49.33% 26.7B
+4.03%-6.07%+26.22%-8.12% 23.36B
Average -1.39%-4.03%+41.23%+130.03% 38.04B
Weighted average by Cap. -0.29%-1.27%+42.96%+155.30%

Financials

2024 2025
Net sales 5.24M 6.98M 6.26M 5.78M 9.8M 663M 9.92M 69.31M 27.52M 347M 26.18M 25.62M 1.1B 9.1M 12.12M 10.87M 10.04M 17.02M 1.15B 17.23M 120M 47.81M 603M 45.48M 44.51M 1.91B
Net income -71.82M -95.57M -85.78M -79.2M -134M -9.08B -136M -950M -377M -4.76B -359M -351M -15.09B 249K 331K 297K 275K 465K 31.47M 471K 3.29M 1.31M 16.5M 1.24M 1.22M 52.31M
Net Debt -27.17M -36.15M -32.44M -29.96M -50.77M -3.43B -51.4M -359M -143M -1.8B -136M -133M -5.71B -18.24M -24.27M -21.78M -20.11M -34.09M -2.31B -34.5M -241M -95.76M -1.21B -91.09M -89.15M -3.83B
Projected Income Statement - Annual - BenevolentAI S.A.
Logo BenevolentAI S.A.
BenevolentAI SA is engaged in creating and applying artificial intelligence (AI) and machine learning in drug discovery. The Company designs its technology to enable scientists to better understand the development of disease mechanisms, discover drug targets and make decisions. It serves patients by leveraging its proprietary and validated Benevolent Platform that integrates AI and science to uncover new biology, predict novel targets and develop drugs for complex diseases. The Benevolent Platform integrates technology, processes, and humans for faster research and development success. Its pipeline includes BEN-8744, BEN-28010, BEN-34712, Parkinson's disease, and Fibrosis. BEN-8744 is developed for the treatment of an ulcerative colitis. The Company provides scientists with a view of disease biology by integrating across all the domains and diverse data types, including omics, molecules, experimental data, literature, pathology, and biological systems.
Employees
173